AbbVie Presents New Analyzes Evaluating RINVOQ (upadacitinib) in Atopic Dermatitis Based on Patient Characteristics and Body Regions at EADV
“These data further highlight the potential of RINVOQ to help relieve itching and rashes in moderate to severe atopic dermatitis, providing further support for its effectiveness on various patient characteristics and areas of the body,” said
P0183: Efficacy of Upadacitinib for Moderate to Severe Atopic Dermatitis: Stratified Analysis of Three Phase 3 Trials by Key Baseline Characteristics: Study Highlights
In this study, researchers presented results assessing whether the efficacy of RINVOQ observed in global phase 3 clinical trials (Measure Up 1, Measure Up 2, and AD Up) differed based on age, weight, gender, disease severity, race / ethnicity, and treatment history. .1 The analysis observed that for the 15 mg and 30 mg treatment groups, the percentage of patients meeting the primary endpoint of
(C) 2021 Electronic News Publishing, source